Medtronic’s RAFT Keeps Hopes Afloat For Shift To CRT In Milder Heart Failure
This article was originally published in The Gray Sheet
Executive Summary
Data reported last week could hasten moves by electrophysiologists to implant price-premium cardiac resynchronization therapy systems rather than conventional defibrillators in patients with earlier stage heart failure.
You may also be interested in...
Regulatory News In Brief
Medtronic, CardioMems go to panel
Regulatory News In Brief
Medtronic, CardioMems go to panel
Blues TEC Assessment Endorses CRT For Mild Heart Failure
Using cardiac resynchronization therapy to treat patients suffering from mild heart failure is supported by existing clinical evidence. That is not the case, however, for asymptomatic patients, according to a new assessment issued by Blue Cross Blue Shield’s Technology Evaluation Center.